Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
This study is currently recruiting participants.
Verified April 2013 by Prism Pharma Co., Ltd.
Sponsor:
Prism Pharma Co., Ltd.
Collaborator:
inVentiv Health Clinical
Information provided by (Responsible Party):
Prism Pharma Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01764477
First received: December 12, 2012
Last updated: April 17, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | February 2015 |
| Estimated Primary Completion Date: | October 2014 (Final data collection date for primary outcome measure) |